Bacitracin
Bacitracin, Bacitracin / / Neomycin / Polymyxin B, Bacitracin / Neomycin / Polymyxin B, Bacitracin / Polymyxin B, Lumi-sporyn, Mycitracin (bacitracin) is a protein pharmaceutical. Bacitracin was first approved as Bacitracin on 1982-01-01. It is used to treat bacterial eye infections, bacterial skin diseases, empyema, pneumonia, and pseudomembranous enterocolitis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Combinations
Lumi-sporyn (generic drugs available since 1982-01-01, discontinued: Cortisporin, Lanabiotic, Mycitracin, Neo-polycin, Ocumycin, Polysporin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bacitracin
+
Polymyxin b sulfate
Bacitracin zinc
+
Hydrocortisone
+
Neomycin sulfate
+
Polymyxin b sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CORTISPORIN | Casper Pharma | N-050416 DISCN | 1982-01-01 | 1 products, RLD |
| CORTISPORIN | Monarch Pharmaceuticals | N-050168 DISCN | 1984-05-04 | 1 products, RLD |
Hide discontinued
Bacitracin zinc
+
Neomycin sulfate
+
Polymyxin b sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LUMI-SPORYN | Casper Pharma | N-050417 RX | 1982-01-01 | 1 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 0.9g triple antibiotic | OTC monograph final | 2022-03-24 |
| 10 person ansi | OTC monograph final | 2010-06-07 |
| 25 person ansi | OTC monograph final | 2010-06-07 |
| 4032 first aid kit | unapproved drug other | 2024-01-22 |
| 4064 first aid kit 4065 first aid kit 4066 first aid kit 4067 first aid kit | unapproved drug other | 2024-01-22 |
| 4125 first aid kit 4241 first aid kit | unapproved drug other | 2024-01-22 |
| 4138 first aid kit | unapproved drug other | 2024-01-22 |
| 4150 first aid kit | unapproved drug other | 2024-01-22 |
| 4152 first aid kit | unapproved drug other | 2024-01-22 |
| 4155 first aid kit | unapproved drug other | 2024-01-22 |
Show 382 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06A: Antibiotics for topical use
— D06AX: Other antibiotics for topical use in atc
— D06AX05: Bacitracin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01X: Other antibacterials in atc
— J01XX: Other antibacterials in atc
— J01XX10: Bacitracin
R: Respiratory system drugs
— R02: Throat preparations
— R02A: Throat preparations
— R02AB: Antibiotic throat preparations
— R02AB04: Bacitracin
HCPCS
No data
Clinical
Clinical Trials
103 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Burns | D002056 | — | T30.0 | 3 | 3 | 1 | 2 | 3 | 9 |
| Dental pulp necrosis | D003790 | — | K04.1 | 3 | — | — | 2 | 2 | 7 |
| Periapical periodontitis | D010485 | EFO_1001391 | K04.5 | 1 | — | — | 1 | 2 | 4 |
| Surgical wound infection | D013530 | — | — | — | — | — | 3 | — | 3 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | 1 | 2 | — | 3 |
| Periapical abscess | D010482 | EFO_1001202 | — | — | 1 | 1 | 1 | 1 | 3 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | 1 | — | 1 | — | 2 |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | — | 1 | 1 | 2 |
| Recurrence | D012008 | — | — | — | — | — | 1 | — | 1 |
| Methicillin-resistant staphylococcus aureus | D055624 | — | — | — | — | — | 1 | — | 1 |
Show 14 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | 1 | — | — | 1 |
| Sick sinus syndrome | D012804 | EFO_0004275 | I49.5 | — | — | 1 | — | — | 1 |
| Syncope | D013575 | HP_0012668 | G90.01 | — | — | 1 | — | — | 1 |
| Heart block | D006327 | — | I45.89 | — | — | 1 | — | — | 1 |
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | — | 1 | — | — | 1 |
| Contact dermatitis | D003877 | — | L25 | — | — | 1 | — | — | 1 |
| Edema | D004487 | HP_0000969 | R60.9 | — | 1 | 1 | — | — | 1 |
| Implant capsular contracture | D057910 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic contact dermatitis | D017449 | — | L23 | — | 1 | — | — | 1 | 2 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 1 | — | — | — | 1 |
| Paranasal sinus diseases | D010254 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | — | — | — | 1 |
| Asymptomatic diseases | D058070 | — | — | 1 | — | — | — | — | 1 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | — | — | — | — | 1 |
| Mammaplasty | D016462 | — | — | 1 | — | — | — | — | 1 |
| Regeneration | D012038 | — | — | 1 | — | — | — | — | 1 |
| Covid-19 | D000086382 | — | U07.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 3 | 3 |
| Pancreatic cyst | D010181 | HP_0001737 | K86.2 | — | — | — | — | 2 | 2 |
| Periapical diseases | D010483 | EFO_0010688 | — | — | — | — | — | 1 | 1 |
| Pancreatitis | D010195 | HP_0001733 | K85 | — | — | — | — | 1 | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 1 | 1 |
| Herpes simplex | D006561 | — | B00 | — | — | — | — | 1 | 1 |
| Finger injuries | D005383 | — | — | — | — | — | — | 1 | 1 |
| Traumatic amputation | D000673 | — | — | — | — | — | — | 1 | 1 |
| Bites and stings | D001733 | — | — | — | — | — | — | 1 | 1 |
| Infectious skin diseases | D012874 | — | — | — | — | — | — | 1 | 1 |
Show 16 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bacitracin |
| INN | bacitracin |
| Description | Bacitracin is a mixture of related cyclic peptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy, first isolated in 1945. These peptides disrupt Gram-positive bacteria by interfering with cell wall and peptidoglycan synthesis.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1 |
Identifiers
| PDB | — |
| CAS-ID | 22601-59-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200558 |
| ChEBI ID | 35862 |
| PubChem CID | 439542 |
| DrugBank | DB00626 |
| UNII ID | 58H6RWO52I (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Bacitracin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Bacitracin
+
Neomycin
+
Polymyxin b
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Bacitracin
+
Polymyxin b
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Bacitracin
+
Polymyxin b
+
Pramoxine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,082 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,674 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use